Wed, Nov 26, 2014, 6:25 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • frankfrazzano frankfrazzano May 18, 2011 12:32 PM Flag

    Celldex is being shopped as we speak!

    http://seekingalpha.com/article/270597-11-potential-biotech-buy-out-targets?source=nasdaq

    if rumour be it, the stock climbs to $5 post ASCO and the buyout unfortunately is at 8! 47M shares at $8 or $376M...Im thinking a number of companies but AZN w/ a war chest of $11B and already experimenting in niche cancer plays could be a suitor?

    <the FDA approved the company's first orphan drug, Vandetanib, which treats metastatic medullary thyroid cancer (MTC). This is a small and profitable market, with 1760 cases in the U.S. annually and a monthly list price of $10,454.>

    GBM/EGFRvIII in the states is what 3K cases and $100K the going rate on specialty cancer meds like Provenge or Ipi?

    looks like a possible fit to me, if not a buyout than a partnership!They AZN need to show growth in the states where they are suffering and this could be that niche cancer market while they make hay in China!

    Frank

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CLDX
20.54+0.16(+0.79%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.